Supplemental Figures from RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
Year: 2023
Type: supplementary-materials
Abstract: Supplemental Figure 1: No clear interaction of molecular subtype with change in TIL score dureing NAC. Supplemental Figure 2: No clear relationship between pre-NAC TILs or change in TILs with RFS or OS. Supplemental Figure 3: No clear association between pre-NAC or post-NAC TILs and total number of targeted alterations identified by targeted NGS. Supplemental Figure 4: A) Percent of high expressers of PD-L1 (>1 standard deviation from the mean) in each molecular subtype in the TCGA breast cancer dataset. Supplemental Figure 5: MEK inhibition down-regulates downstream ERK signalling and inhibits proliferation of TNBC murine breast cancer lines AT3ova and 4T1.9 in vitro. Supplemental Figure 6: Efficacy of selumetinib and anti-PD-L1 therapy in MMTV-Neu models. Supplemental Figure 7: Pharmacodynamic activity of trametinib and selumetinib in vivo.
Authors: Sherene Loi, Sathana Dushyanthen, Paul A. Beavis, Roberto Salgado, Carsten Denkert, Peter Savas, Susan Combs, David L. Rimm, Jennifer M. Giltnane, Monica V. Estrada, Violeta Sánchez, Melinda E. Sanders, Rebecca S. Cook, Mark A. Pilkinton, Simon A. Mallal, Kai Wang, Vincent A. Miller, Phil J. Stephens, Roman Yelensky, Franco D. Doimi, Henry Gómez, Sergey V. Ryzhov, Phillip K. Darcy, Carlos L. Arteaga, Justin M. Balko
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362397338